Literature DB >> 8759884

Cryopreserved human bone marrow stroma is fully functional in vitro.

A Nicol1, M Nieda, C Donaldson, P Denning-Kendall, C Truman, B Bradley, J Hows.   

Abstract

Human-marrow long-term culture (LTC) enables maintenance of both stromal and haemopoietic elements of normal bone marrow (NBM) in vitro for 4-6 months. Stroma-based cultures are critical for quantitation of long-term culture initiating cells (LTC-IC), the most primitive human haemopoietic cells measurable in vitro. Supply of NBM can be sporadic, and up to 3-4 weeks in culture is required for stromal maturity. Stroma availability for experimental purposes can therefore be limited. Efforts to produce transformed human and transfected murine stromal cell lines comparable to NBM stroma have had some success. As an alternative, we investigated cryopreserved NBM and cryopreserved performed stroma. Function of cryopreserved and control fresh NBM stroma was similar when evaluated for up to 12 weeks in LTC. We have also demonstrated that stroma derived from cryopreserved NBM or performed cryopreserved NBM stroma can sustain third-party haemopoiesis as efficiently as fresh NBM stroma in LTC. Batched cryopreserved stroma is a convenient, rapidly available, source of functional stroma which avoids the logistic difficulties and lack of standardization associated with stroma from fresh NBM. This important advance will enhance the use of stroma-based LTC in studies of human haemopoiesis.

Entities:  

Mesh:

Year:  1996        PMID: 8759884     DOI: 10.1046/j.1365-2141.1996.d01-1812.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Antagonizing Retinoic Acid Receptors Increases Myeloid Cell Production by Cultured Human Hematopoietic Stem Cells.

Authors:  Geoffrey Brown; Aleksandra Marchwicka; Alan Cunningham; Kai-Michael Toellner; Ewa Marcinkowska
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2016-07-13       Impact factor: 4.291

Review 2.  Surfing the clinical trials of mesenchymal stem cell therapy in ischemic cardiomyopathy.

Authors:  Iman Razeghian-Jahromi; Anthony G Matta; Ronan Canitrot; Mohammad Javad Zibaeenezhad; Mahboobeh Razmkhah; Anahid Safari; Vanessa Nader; Jerome Roncalli
Journal:  Stem Cell Res Ther       Date:  2021-06-23       Impact factor: 6.832

3.  Impact of age on the efficacy of bone marrow mononuclear cell transplantation in experimental stroke.

Authors:  Daniel-Christoph Wagner; Mitja Bojko; Myriam Peters; Marlene Lorenz; Cornelia Voigt; Alexander Kaminski; Dirk Hasenclever; Markus Scholz; Alexander Kranz; Gesa Weise; Johannes Boltze
Journal:  Exp Transl Stroke Med       Date:  2012-08-24

Review 4.  Mesenchymal stem cells for regenerative therapy: optimization of cell preparation protocols.

Authors:  Chiho Ikebe; Ken Suzuki
Journal:  Biomed Res Int       Date:  2014-01-06       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.